Group items tagged

Technology incorporation and adapting to gig economy norms is what going to make the healthcare industry powerful. How it can be possible, learn more here.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients. However, there are a few commonly used MIPS Quality Measures that both doctors can use and register their value-based care. Last year, the condition was a little different with MIPS data submission, but for MIPS 2021, the requirements are seen to be a bit flexible, and the corona pandemic is the reason for that. From Advance Care Plan to the MIPS Quality Measures, associated with the common illnesses and conditions, eligible clinicians have to check which measures are most suitable for their practice. An easy way to go through the process of MIPS 2021 reporting is to find a MIPS Qualified Registry. They have the resources and the trained MIPS consultants to help you meet your objectives.

Medical doctor (MD) and Doctor of Osteopathic Medicine (DO) are two different entities that work with the same mission but different approaches, as DO goes with a holistic approach for treatment. QPP MIPS, being an incentive payment program, allows them both to deliver quality healthcare to patients.

MIPS eligible clinicians! Do you know if you report MIPS 2021 as per the proper guidelines, you can earn up to 5% incentives and even qualify for a bonus pool worth $500 million?

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted the following price concessions for November 2021. Contractors can find information on the price concessions and learn about the process involved on PSNC's website. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted. PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2021 Drug Tariff price.

MIPS 2020 feedback is available for review by CMS. Clinicians can even ask for a targeted review in case of any error in the points or payment adjustments.

CMS extends the deadline for MIPS 2020 targeted review to help eligible clinicians check their data, score, payment adjustments, and apply for reweighting in case of any effect.

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted final price concessions to further items for the month of November 2021. A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted. Contractors can find information and learn about the process involved on PSNC's website. Check pharmacy business website for price concession list november 2021.

A Nottingham-based pharmacist has been struck off the General Pharmaceutical Council (GPhC) register for bringing "the profession into to disrepute" by stealing hundreds of thousands of pounds in a bid to settle his gambling debt. Peter Sameh Saad (33) spun a web of lies and duped a friend out of more than half a million pounds to fund his addiction and pretended he had "serious if not terminal" testicular cancer. "It is difficult to imagine a more heinous fraud than one predicated on feigning a cancer diagnosis", a GPC panel ruled. Saad committed three frauds on a total of £536,689.95 between September 2018 and May 2019. First, he tricked a friend, whom he knew through his local church, into sending him around £288,200 by claiming that his newly-purchased pharmacy in US was "seized" by the authorities over visa issues and that he "had some difficulty making the mortgage payments". Later Saad conned the same friend, named only as 'Person A' in court documents, into sending him a total of £127,150 by lying about a non-existent cancer diagnosis and private treatment. Finally, he extracted a further £121,339.95 from an investments and credit group (named Company A) of which his friend was chief executive after inviting him to set up a 'pharmaceutical warehouse', a plan that "impressed Person A and he agreed to invest in the business."

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

Becoming a pharmacist is a rewarding and fulfilling career path. Still, many aspiring pharmacists graduate with substantial student loan debt, which can be daunting to manage while starting their careers. However, various pharmacist loan forgiveness programs can ease this financial burden and pave the way to debt-free living. This article will explore six pharmacist loan forgiveness programs that can help pharmacists achieve financial freedom. Public Service Loan Forgiveness (PSLF) According to Bankrate, the Public Service Loan Forgiveness (PSLF) program is a federal program designed to forgive the remaining balance on federal Direct Loans after 120 qualifying monthly payments while working full-time for a qualifying employer. Pharmacists who work for non-profit organizations, government agencies, or public health organizations may be eligible for this program. Health Professional Shortage Areas (HPSAs) Loan Repayment Program The Health Professional Shortage Areas (HPSAs) Loan Repayment Program encourages healthcare professionals, including pharmacists, to work in areas with a shortage of healthcare providers. Pharmacists who commit to working in designated HPSAs for a specified period can receive loan repayment assistance.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

The National Pharmacy Association (NPA) is calling on NHS England and its member to pause and reflect before further implementing the pharmacy contraception service. NPA board met on Tuesday (25 April) to discuss the Pharmacy Contraception Service and the board decided that - with the community pharmacy sector at breaking point - it cannot support the immediate roll out of this service. The association believes that with no new funding for the service, and all existing funds in effect already allocated to other pharmacy activity, any payments to the sector for delivery of the oral contraception service will ultimately be clawed back by NHS England. Tweeting after the meeting yesterday, the NPA said: "We can't tell pharmacy owners what they can and can't do. But we can tell them the facts; fact number one is that with no new funding currently available everyone will be a loser from the implementation of this service on the current terms." NPA Vice-Chair Jay Badenhorst added: "We cannot be expected to take on more and more services without the increase in funding necessary to deliver them effectively. Meanwhile, taking on additional work when current workload already exceeds capacity risks impacting negatively on the overall quality of care people experience in pharmacies. We still believe this could, in future, be a great new pharmacy service, but not without the extra funding necessary to deliver it safely and effectively. We want to offer women this extra support, but if it's worth doing it's worth doing properly."

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.

Pharmacists working in Northern Ireland think the retention fees are too high, and most would prefer to pay in instalments, if that option is available, amid the increased living costs, a new survey has found. 97 per cent of the respondents to the survey, conducted by the Pharmacists' Defence Association (PDA) of its Northern Irish members, felt the fees were too high. Four in five said they would opt to pay in instalments if this option were available to them in light of the challenges of significant one-off payments. On average, the fees accounted for 23 per cent of a pharmacist's take-home pay for one month, and 98 per cent did not see any value added to their professional standing for the sum, according to the survey. The PDA said the respondents also reported feeling disadvantaged among their colleagues in terms of how fees are collected, with many also wondering why the registration fee was not offset for those on maternity leave or working reduced or flexible hours.

Boots pharmacists will receive a pay rise of 4.5 per cent as the pharmacy multiple and PDA Union jointly announce this year's pay settlement. Following discussions between Boots management services and the PDA Union negotiators, the agreement was reached in relation to this year's pay claim, effective from 1 November 2022. The union also announced that those who have already had a pay increase on or since 1 August 2022, where that increase has been less than 4.5 per cent, a 'top up' increase will be provided, from 1 November 2022, to ensure that all eligible members of the bargaining unit receive a pay increment of not less than 4.5 per cent in 2022. Boots and the PDA Union have agreed an increase to the pay of those above the maximum market range by 4 per cent with an additional 0.5 per cent non-consolidated payment.

The Pharmaceutical Services Negotiating Committee (PSNC) has announced that the new Pharmacy Quality Scheme (PQS) for this year will officially begin on October 10. From previous scheme £75m funding is also available and contractors will be able to claim an 'Aspiration payment' if they wish to, later this year. PSNC, the Department of Health and Social Care and NHS England have agreed the arrangements for the 2022/23 PQS, as well as those for the 2023/24 PQS, with a focus on supporting recovery from Covid-19 and wider national health priorities. The committee said: "In our negotiations on the scheme, PSNC has managed to reduce the scope of this year's PQS so that the estimated contractor costs and time required to complete the criteria will be below those associated with the original NHS proposals for the scheme." "A further reduction in scope has also been agreed due to the delayed start of the 2022/23 PQS. PSNC hopes that this, along with arguing for more realistic targets across the scheme, will help reduce the impact on contractor workload, at what continues to be a very busy and pressured period for the sector."

Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of £17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating Committee (PSNC). In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of £4.24. Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has increased from £4.24 to £17.77 for July 2022. PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."

The Pharmaceutical Services Negotiating Committee (PSNC) chief executive Janet Morrison has assured contractors that PSNC will continue to raise with the new prime minister all concerning issues that are bothering pharmacy businesses. She felt the "fixed five-year funding settlement that is declining in real terms" was one of the serious factors that is putting a lots of pressure on contractors. PSNC has provided a compelling portfolio of evidence on the impact that pressures are having on the sector, and requested urgent additional funding, she said. Morrison, in her video message shared yesterday (August 24), urged contractors to keep sharing and sending evidences to act on their behalf. She said she is aware "this one of the toughest periods for the businesses" and "I believe that it demands more action from the government." Morrison assured the sector she was aware that contractors were also facing difficulties in "dealing with global medicines market and the challenges on been able to procure medicines within the drug tariff." "I know how hard it is to see the future sustainability of your businesses. I can see you are facing serious workforce pressure, rising cost, shortage of pharmacists, inflation pressure. I know your using facing increase in demand from the patients who has given up on their GPs and turning to you for support and advice."

The Pharmaceutical Services Negotiating Committee (PSNC) has developed a webtool to help community pharmacy contractors estimate the impact on their payments under the new discount deduction system. The calculator aims to illustrate the changes to discount deduction that a pharmacy could experience during the transition to the new arrangements from October 2022 to January 2024, when the new system will be fully in place. PSNC's calculator requires contractors to input information about their individual pharmacy dispensing mix (i.e. split of reimbursement by appliances, brands and generics) to provide an estimate for the level of impact the new discount deduction system will have. "The impact on individual pharmacies cannot be estimated without using dispensing mix data, meaning that any estimates which do not take this into account will not be reliable," said PSNC. For years many contractors have been frustrated by how discount is applied to their accounts and have often raised concerns about the blanket nature of its application to PSNC.

A community pharmacy contractor would be charged £25 if a paper prescription bundle is submitted late to the NHSBSA. "A charge for processing of a late bundle would only apply if a contractor cannot provide evidence, where requested by the NHSBSA, that their bundle was submitted using secure track and trace delivery no later than the 5th day of the following month in which supply was made," said the Pharmaceutical Services Negotiating Committee (PSNC). "Where evidence is submitted, no administrative deduction will be made. If no evidence is provided within the required time, then an administrative deduction will be made from the next Schedule of Payments. The deduction which will appear on schedules as 'Late Fee' under the section "Details of other amounts authorised"." Since the introduction of an administrative charge for late bundle submissions, 16 contractors received a fine for submitting their March prescription bundles late.